Kezar Life Sciences to Present at the Jefferies London Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Kezar Life Sciences (Nasdaq: KZR) announced its participation in a fireside chat at the Jefferies London Healthcare Conference, available for on-demand viewing from November 18 at 3:00 a.m. EST. The webcast can be accessed through the Events & Presentations section on Kezar's website, with an archived replay available for 90 days post-conference. The company focuses on developing treatments for immune-mediated and oncologic disorders, with KZR-616 in Phase 2 trials and KZR-261 in Phase 1 trials.
Positive
None.
Negative
None.
Insights
Analyzing...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference. The presentation will be available for on-demand viewing starting Thursday, November 18 at 3:00 a.m. EST.
A webcast of the event may be accessed at the “Events & Presentations” section of Kezar’s website at https://www.kezarlifesciences.com/investors/news-events/ir-calendar. Kezar Life Sciences will maintain an archived replay of the webcast on its website for 90 days after the conference.
About Kezar Life Sciences
Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. KZR-616, its lead asset, is a selective immunoproteasome inhibitor being evaluated in Phase 2 clinical trials in lupus nephritis, dermatomyositis, and polymyositis. Additionally, KZR-261, is the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com.
When will Kezar Life Sciences participate in the Jefferies London Healthcare Conference?
Kezar Life Sciences will participate in the Jefferies London Healthcare Conference on November 18, starting at 3:00 a.m. EST.
How can I access the Kezar Life Sciences fireside chat?
The fireside chat will be available for on-demand viewing in the 'Events & Presentations' section of Kezar's website.
What is KZR-616?
KZR-616 is Kezar Life Sciences' lead asset, a selective immunoproteasome inhibitor in Phase 2 clinical trials for lupus nephritis, dermatomyositis, and polymyositis.
What is KZR-261?
KZR-261 is the first anti-cancer clinical candidate from Kezar, currently undergoing a Phase 1 trial to assess safety and preliminary tumor activity in solid tumors.
How long will the webcast of the Kezar Life Sciences conference be available?
The archived replay of the webcast will be available for 90 days after the conference.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
